 |
|
Natural History of Human T-Lymphotropic Virus 1–Associated Myelopathy
A 14-Year Follow-up Study
Stéphane Olindo, MD;
Philippe Cabre, MD;
Agnes Lézin, PhD;
Harold Merle, MD;
Martine Saint-Vil, MD;
Aissatou Signate, MD;
Mickael Bonnan, MD;
Aurelie Chalon, PhD;
Lionel Magnani, MD;
Raymond Cesaire, MD, PhD;
Didier Smadja, MD
Arch Neurol. 2006;63:1560-1566.
Background The progression of neurological disability in human T-lymphotropic virus 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains undefined.
Objectives To determine the time course of disability scores and to identify predictors of outcome among patients with HAM/TSP.
Design Clinical 14-year follow-up study.
Setting University hospital.
Patients One hundred twenty-three patients with HAM/TSP.
Main Outcome Measures We determined time from onset to the following 4 Kurtzke Disability Status Scale (DSS) end points: scores of 6 (unilateral aid required), 6.5 (bilateral aid required), 8 (wheelchair confinement), and 10 (death related to the disease). Times to reach selected DSS scores were estimated using the Kaplan-Meier method. Univariate and multivariate analyses identified variables related to the rate of progression to DSS 8. The HTLV-1 proviral loads were also assessed.
Results The disability of the cohort progressed throughout the follow-up period. The median times from onset to DSS 6, 6.5, and 8 were 6, 13, and 21 years, respectively. The median time from DSS 6 to DSS 8 was 8 years; DSS 10 was reached by one fourth of the patients within 20 years. Age at onset of 50 years or older and high HTLV-1 proviral load were associated with a shorter time to DSS 8 (P = .01 and P = .02, respectively). A shorter time to DSS 6 significantly adversely affected the time to progression from DSS 6 to DSS 8.
Conclusions Human T-lymphotropic virus 1–associated myelopathy/tropical spastic paraparesis is a rapidly disabling disease. Monitoring for HTLV-1 proviral load is recommended in future therapeutic trials.
Author Affiliations: Departments of Neurology (Drs Olindo, Cabre, Saint-Vil, Signate, Bonnan, and Smadja), Viro-Immunology (Drs Lézin, Chalon, and Cesaire), Ophthalmology (Dr Merle), and Statistics (Dr Magnani), University Hospital of Fort de France, Fort de France, Martinique.
RELATED LETTERS
Other Important Aspects of Human T-Lymphotropic Virus 1–Associated Myelopathy
Marco A. Lima, Ana C. Leite, Marcus T. Silva, and Abelardo Q. Araújo
Arch Neurol. 2007;64(7):1059.
EXTRACT
| FULL TEXT
Other Important Aspects of Human T-Lymphotropic Virus 1–Associated Myelopathy—Reply
Stéphane Olindo, Agnès Lézin, and Didier Smadja
Arch Neurol. 2007;64(7):1059-1060.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Other Important Aspects of Human T-Lymphotropic Virus 1-Associated Myelopathy
Lima et al.
Arch Neurol 2007;64:1059-1059.
FULL TEXT
Other Important Aspects of Human T-Lymphotropic Virus 1-Associated Myelopathy--Reply
Olindo et al.
Arch Neurol 2007;64:1059-1060.
FULL TEXT
|
